Crinetics Pharmaceuticals is a biotechnology business based in the US. Crinetics Pharmaceuticals shares (CRNX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $53.14 – the same closing value as a week prior. Crinetics Pharmaceuticals employs 290 staff and has a trailing 12-month revenue of around $1.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $53.14 |
|---|---|
| 52-week range | $25.75 - $55.78 |
| 50-day moving average | $51.87 |
| 200-day moving average | $45.63 |
| Wall St. target price | $70.38 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.76 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $53.14 from 2024-10-11
| 1 week (2024-10-04) | 53.14 |
|---|---|
| 1 month (2024-09-13) | -1.23% |
| 3 months (2024-07-12) | -0.99% |
| 6 months (2024-04-12) | 19.17% |
| 1 year (2023-10-13) | 82.55% |
|---|---|
| 2 years (2022-10-13) | 189.91% |
| 3 years (2021-10-13) | 171.26% |
| 5 years (2019-10-11) | 222.45% |
| Revenue TTM | $1.4 million |
|---|---|
| Gross profit TTM | $-125,488,000 |
| Return on assets TTM | -28.27% |
| Return on equity TTM | -47.66% |
| Profit margin | 0% |
| Book value | $10.47 |
| Market Capitalization | $4.1 billion |
TTM: trailing 12 months
We're not expecting Crinetics Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Crinetics Pharmaceuticals's shares have ranged in value from as little as $25.75 up to $55.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crinetics Pharmaceuticals's is 0.636. This would suggest that Crinetics Pharmaceuticals's shares are less volatile than average (for this exchange).
Crinetics Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.